NEW YORK, NY, April 8, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with its partner, global oral pill vaccine pioneer Immunitor (Thailand) Co., Ltd, the Company is today launching its unique M.vaccae and magnesium dietary supplement in the $18 billion Anxiety and Stress market.
NEW YORK, NY, April 7, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises the Company is launching https://MaxCellLife.com today specializing in the sales and marketing of science driven supplement and skincare products.
NEW YORK, NY, March 12, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with its partner, global oral pill vaccine pioneer Immunitor, it will be launch a unique M.vaccae and Magnesium dietary supplement in the $18 billion Anxiety and Stress market.
NEW YORK, NY, March 3, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) in response to recent global media coverage of a scramble or race to develop oral pill vaccines for disease treatment and/or for application to viruses including SARS-CoV-2, advises that, Immunitor, its Licensor and Partner is well recognized globally as a pioneer in oral vaccines development.
NEW YORK, NY, February 18, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that it continues to work with Immunitor, its partner and Licensor, to progress further research and development of its breakthrough therapeutic vaccines, and for several unique supplements.
NEW YORK, NY, January 28, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that as SARS-CoV-2 continues to spread, and reports of increases in daily infections, hospitalizations, and deaths are becoming regular, Key Capital plans to market its Immunitor partnered potentially therapeutic oral pill as a supplement commencing early February.
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine
NEW YORK, NY, January 6, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis.
